PT. Tofflon Science and Technology Indonesia is Tofflon Science and Technology Group Co. Ltd.'s Indonesia Subdiory. Tofflon Science and Technology Group Co. Ltd.(Short for “Tofflon”, Stock Code: SZ 300171) was founded in 1993. It is a comprehensive pharmaceutical equipment supplier to provide process support, core equipments, integrated system and pharma engineering for the pharma and biotech industry in the world. Since its foundation, Tofflon has supplied more than 8000 equipments and systems for 2000 pharmaceutical companies across over 40 countries and regions in the world which have been widely applied in the fields of liquid and Lyo injectables, chemical API, bioengineering and pharma packaging, etc.Tofflon focuses on studying drug manufacture science and process equipment manufacture science, practices drug process knowledge integration with pharma equipment knowledge. Taking “Synergy Global Advanced Technologies” strategy, Tofflon builds comprehensive development institute in Shanghai headquarters, is building design houses and technical canter in USA, Europe and India, establishes joint ventures and technology collaboration with the technical partners from USA, Europe and Japan. Furthermore Tofflon has built five modern pharmaceutical equipment manufacturing bases with global competitiveness. It can provide competitive pharmaceutical equipment and system solutions valuable for today and future’s competence improvement of the pharma and biotech companies.To commit to its mission “Expertise in Pharmaceutical Industry”, Tofflon will continuously work with pharmaceutical industry to face and meet the challenges and pressures in the industry through developing “innovative drug manufacturing science” and building “advanced drug manufacturing platform”. In the following years, Tofflon will dedicate itself to grow from “China Tofflon to Global Tofflon”, from “Equipment Supplier to Solution Provider” so as to grow up to a total solution provider of pharmaceutical manufacturing systems and engineering for the global pharma and biotech industry to contribute to the maximum benefits and welfare of its served society, customers, stockholders, employees and their families.